Tia has been Live Science's associate editor since 2017. Prior to that, Tia was a senior writer for the site, covering physics, archaeology and all things strange. Tia's work has appeared in Scientific American, Wired.com, and the Milwaukee Journal Sentinel. Tia grew up in Texas and has an undergraduate degree in mechanical engineering from the University of Texas at Austin, a master's degree in bioengineering from the University of Washington and a graduate certificate in science writing from the University of California Santa Cruz. When she's not editing stories, Tia enjoys reading dystopian fiction and hiking.
Zammit and colleagues’ findings were supported in a 3-year longitudinal study of the relationship between self-reported cannabis use and psychosis in a community sample of 4848 people in the Netherlands (van Os et al., 2002). Van Os and colleagues reported that cannabis use at baseline predicted an increased risk of psychotic symptoms during the follow-up period in individuals who had not reported psychiatric symptoms at baseline. There was a dose–response relationship between frequency of cannabis use at baseline and risk of psychotic symptoms during the follow-up period. These relationships persisted when they statistically controlled for the effects of other drug use. The relationship between cannabis use and psychotic symptoms was also stronger for cases with more severe psychotic symptoms.
Several of the cannabinoids are reputed to have medicinal potential: THC for glaucoma, spasticity from spinal injury or multiple sclerosis, pain, inflammation, insomnia, and asthma; CBD for some psychological problems. The Netherlands firm HortaPharm developed strains of Cannabis rich in particular cannabinoids. The British firm G.W. Pharmaceuticals acquired proprietary access to these for medicinal purposes, and is developing medicinal marijuana. In the US, NIH (National Institute of Health) has a program of research into medicinal marijuana, and has supplied a handful of individuals for years with maintenance samples for medical usage. The American Drug Enforcement Administration is hostile to the medicinal use of Cannabis, and for decades research on medicinal properties of Cannabis in the US has been in an extremely inhospitable climate, except for projects and researchers concerned with curbing drug abuse. Synthetic preparations of THC—dronabinol (Marinol®) and nabilone (Cesamet®)—are permitted in some cases, but are expensive and widely considered to be less effective than simply smoking preparations of marijuana. Relatively little material needs to be cultivated for medicinal purposes (Small 1971), although security considerations considerably inflate costs. The potential as a “new crop” for medicinal cannabinoid uses is therefore limited. However, the added-value potential in the form of proprietary drug derivatives and drug-delivery systems is huge. The medicinal efficacy of Cannabis is extremely controversial, and regrettably is often confounded with the issue of balancing harm and liberty concerning the proscriptions against recreational use of marijuana. This paper is principally concerned with the industrial uses of Cannabis. In this context, the chief significance of medicinal Cannabis is that, like the issue of recreational use, it has made it very difficult to rationally consider the development of industrial hemp in North America for purposes that everyone should agree are not harmful.
Toggle navigationNewsConditionsConditionsADHDAllergic rhinitisAlzheimer's diseaseAnxietyArthritisAsthmaAutismBowel cancerBreast cancerCancerChesty coughsChickenpoxChlamydiaCholesterolCoeliac diseaseCommon coldConstipationCOPDDepressionDiabetesDiverticulitisEpilepsyFatty liverFibromyalgiaGenital herpesGORD (reflux)GoutHaemorrhoidsHair lossHeart attackHepatitisHiatus herniaHigh blood pressureHIV and AIDSImpotenceMenopauseMigraineNeuropathic painOsteoporosisPainPeptic ulcersPneumoniaProstate cancerScabiesSchizophreniaSciaticaShinglesSinusitisSkin cancerStrokeThyroid gland disordersUrticaria (hives)Vaginal thrushVasectomyVertigoVulval problemsWhooping coughMedicinesMedicinesAugmentinAvilChlorsigDaklinzaDuromineEndepEndoneHarvoniLevlenLyricaMersyndolMetrogylPanadeine FortePanefcortelonePrimolutRestavitSovaldiStemetilViagraZentelFind a MedicineMedicines CentreSymptomsSymptomsBack painChildhood rashesCommon coldDepressionFeverFibromyalgiaHeart attackHeel painHerpesLeg acheLeg crampsSciaticaShinglesStrokeVaginal thrushVertigoMore symptomsLifestyleHealthy LifestyleAddictionsAlcoholCholesterolExerciseHealthy eatingHealthy WeightHeart healthImmunisationSleepSmokingStress Health Centres Nutrition & WeightSports & FitnessTools Medical Dictionary Medical Dictionary
The objectivity of scientific evaluation of the medicinal value of marijuana to date has been questioned. In the words of Hirst et al. (1998): “The ...status of cannabis has made modern clinical research almost impossible. This is primarily because of the legal, ethical and bureaucratic difficulties in conducting trials with patients. Additionally, the general attitude towards cannabis, in which it is seen only as a drug of abuse and addiction, has not helped.” In a recent editorial, the respected journal Nature (2001) stated: “Governments, including the US federal government, have until recently refused to sanction the medical use of marijuana, and have also done what they can to prevent its clinical testing. They have defended their inaction by claiming that either step would signal to the public a softening of the so-called ‘war on drugs.’... The pharmacology of cannabinoids is a valid field of scientific investigation. Pharmacologists have the tools and the methodologies to realize its considerable potential, provided the political climate permits them to do so.” Given these current demands for research on medicinal marijuana, it will be necessary to produce crops of drug types of C. sativa.
Hemp is not the same as marijuana. One really has nothing to do with the other. Hemp was made illegal back in the days when cotton was king in the south and southern cotton plantation owners did not want the competition. They lobbied for, and got a law against hemp being grown nationwide. It never had to do with drugs at that time, and still doesn’t. As always, money and government go hand in hand. Now, recently, South Carolina has legalized growing hemp again, which is the only state in 50 to do so. We will hope for more enlightened agri-business legislation across the nation, soon.
“The brain has these receptors that respond to endocannabinoids, which are neurotransmitters that are naturally produced in the body and brain,” says Jerald Simmons, a neurologist at Houston’s Comprehensive Sleep Medicine Associates. “Some of the cannabinoids in the marijuana plant are very similar to the endocannabinoids in the brain, and they act on the same receptors.”
There is concern that cannabis may contribute to cardiovascular disease, but as of 2018, evidence of this relationship was unclear. Cannabis is believed to be an aggravating factor in rare cases of arteritis, a serious condition that in some cases leads to amputation. Because 97% of case-reports also smoked tobacco, a formal association with cannabis could not be made. If cannabis arteritis turns out to be a distinct clinical entity, it might be the consequence of vasoconstrictor activity observed from delta-8-THC and delta-9-THC. Other serious cardiovascular events including myocardial infarction, stroke, sudden cardiac death, and cardiomyopathy have been reported to be temporally associated with cannabis use. Research in these events is complicated because cannabis is often used in conjunction with tobacco, and drugs such as alcohol and cocaine. These putative effects can be taken in context of a wide range of cardiovascular phenomena regulated by the endocannabinoid system and an overall role of cannabis in causing decreased peripheral resistance and increased cardiac output, which potentially could pose a threat to those with cardiovascular disease. There is some evidence from case reports that cannabis use may provoke fatal cardiovascular events in young people who have not been diagnosed with cardiovascular disease. Smoking cannabis has also been shown to increase the risk of myocardial infarction by 4.8 times for the 60 minutes after consumption.
Tocopherols. Tocopherols are major antioxidants in human serum. Alpha- beta-, gamma- and delta-tocopherol represent the vitamin E group. These fat-soluble vitamins are essential for human nutrition, especially the alpha-form, which is commonly called vitamin E. About 80% of the tocopherols of hempseed oil is the alpha form. The vitamin E content of hempseed is comparatively high. Antioxidants in hempseed oil are believed to stabilize the highly polyunsaturated oil, tending to keep it from going rancid. Sterols in the seeds probably serve the same function, and like the tocopherols are also desirable from a human health viewpoint.
From what I understand, CBD derived from the hemp plant does not have the side effects mentioned above, other than possibly to help reduce the amount of Coumadin/Warfarin needed – either way, a patient on this drug needs to be monitored and regularly tested anyway with their doctor. CBD derived from the marijuana plant (will contain THC) may have them, I do not know, maybe that’s why you mention them. One of the many reasons people take Hemp CBD is that it does NOT have the side effects! People take the Hemp version to help with feelings of fatigue, irritability & anxiousness, it does cause it! It helps to bring the body into balance.
The Medical Marijuana Industry here has glommed on to the “Alternative” Medicine Industry models. I half expected the Dispensary employee to explain that because the Hemp Oil was in contact with CBD, it was the same thing. The Industry even has high quality magazines where they advertise and give advice, most contain a lot of pseudo science. The refer to Pharma Industry Studies as proof that CBD works.
For many, the medical and therapeutic potential of cannabis is what makes legalizing the marijuana plant such an important political and social task. Federal prohibition has established barriers to comprehensive cannabis research in the United States. However, researchers in other countries continue to make significant contributions to our knowledge of the cannabis plant and how it affects the human body.
Hemp is the non THC variety of the Cannabis Sativa plant. Hemp and marijuana are often confused, learn more about the difference on our hemp vs. marijuana page. The fiber, seeds and oil are incredible valuable and is why hemp is often called a “cash crop”. Hemp is a very hearty plant and grows very quickly in very diverse soil conditions. Cultivation of hemp for industrial purposes has been done by many civilizations for over 12,000 years. Industrial hemp was the desired fiber used to manufacture rope, canvas, paper, and clothing until alternative textiles and synthetics for these purposes were discovered. Although China has been the largest hemp producer over the years, other countries such as Australia and Canada are catching up. It has been illegal for anyone to grow hemp in the United States as hemp is illegal under the marijuana prohibition act but Colorado has changed the laws and paved the way for industrial hemp production again in the United States(see hemp history). Now hemp oils, CBD, hemp plastics, hemp building materials and many hemp fiber products can be seen and purchased on the market. Hemp is truly an amazing plant with the potential to help “green up” many industries.
The Hemp Farming Act of 2018, part of the 2018 Farm Bill signed by President Donald Trump December 20, 2018, changed hemp from a controlled substance to an agricultural commodity, legalizing hemp federally, which made it easier for farmers to get production licenses, get loans to grow hemp, and allowed them to get federal crop insurance.
Last May, not long before Canada legalized the recreational use of marijuana, Beau Kilmer, a drug-policy expert with the RAND Corporation, testified before the Canadian Parliament. He warned that the fastest-growing segment of the legal market in Washington State was extracts for inhalation, and that the mean THC concentration for those products was more than sixty-five per cent. “We know little about the health consequences—risks and benefits—of many of the cannabis products likely to be sold in nonmedical markets,” he said. Nor did we know how higher-potency products would affect THC consumption.
I wanted to tell people here that CBD has been very effective for my anxiety, and helps with insomnia. For me, it was a cumulative effect, after a week of one dropper of oil, I can sleep very well at night. I feel like I am not polluting my body with commercial pharmaceuticals. I wish everyone here the best, and hope it works for you as well as it has for me.
Because C. sativa has been a neglected crop for so long in North America, there are only negligible genetic resources available on this continent. Most germplasm stocks of hemp are in Europe, and the largest and most important collection is the Vavilov Institute gene bank in Leningrad. Figure 11 shows THC concentrations in the Vavilov collection, as well as in our own collection, largely of European germplasm. A disturbingly high percentage of the collections have THC levels higher than 0.3%, making it difficult to incorporate these into breeding programs.
Hemp, or industrial hemp (from Old English hænep), typically found in the northern hemisphere, is a variety of the Cannabis sativa plant species that is grown specifically for the industrial uses of its derived products. It is one of the fastest growing plants and was one of the first plants to be spun into usable fiber 10,000 years ago. It can be refined into a variety of commercial items including paper, textiles, clothing, biodegradable plastics, paint, insulation, biofuel, food, and animal feed.
^ Jump up to: a b c Whiting, PF; Wolff, RF; Deshpande, S; Di Nisio, M; Duffy, S; Hernandez, AV; Keurentjes, JC; Lang, S; Misso, K; Ryder, S; Schmidlkofer, S; Westwood, M; Kleijnen, J (23 June 2015). "Cannabinoids for Medical Use: A Systematic Review and Meta-analysis" (PDF). JAMA. 313 (24): 2456–2473. doi:10.1001/jama.2015.6358. hdl:10757/558499. PMID 26103030.
Moreover, scientists at the Cajal Institute showed promising results in regards to CBD and Multiple Sclerosis. They used animal models and cell cultures to find that CBD reversed inflammatory responses; within only ten days, mice that were used in the study had superior motor skills and showed progression in their condition. To date, there have been well over 20,000 published scientific articles on cannabinoids and their related effects on all sorts of medical ailments.
A clinical endocannabinoid deficiency has been postulated to be operative in certain treatment-resistant conditions (Russo 2004), and has received recent support in findings that anandamide levels are reduced over controls in migraineurs (Sarchielli et al 2006), that a subset of fibromyalgia patients reported significant decreased pain after THC treatment (Schley et al 2006), and the active role of the ECS in intestinal pain and motility in irritable bowel syndrome (Massa and Monory 2006) wherein anecdotal efficacy of cannabinoid treatments have also been claimed.
The Food and Drug Administration (FDA) does not consider CBD or products that contain CBD to be dietary supplements. This is because CBD has been studied and approved for use as a new drug to treat epilepsy, which means it is outside the definition of a dietary supplement.5 There may be products available that are marked as dietary supplements, however the amount of cannabidiol they claim to contain may not be accurate.
would take the oil and put about 2 or 3 dots behind his knee and to his surprise, the tingling went away right away. I found this hard to believe, but after hearing from some other people on the benefits of CBD, I decided to give it a try. It didn’t come cheap. I had to pay 50 dollars for an oz. but it was whole plant in full spectrum. The first night that I got restless leg syndrome and went into the bathroom and put 3 dots behind my knees on both legs it was only a matter of seconds before I
The tricky part is that there's some evidence suggesting CBD works best for pain when combined with a little THC, says Dr. Danesh. "Depending on what type of pain you have, you might be able to do just CBD, but sometimes you need CBD and THC." This makes accessing a product that will actually help you more difficult due to different regulations in each state. In New York, where Dr. Danesh practices, for example, CBD is available over the counter. But as soon as you add THC, you need a prescription.
Canada is specialized on oilseed production and processing, so that hemp oil and grain are much more suitable than fiber. Because of the extensive development of oilseeds in Canada, there is extensive capacity to produce high-quality cold-pressed hemp oil. Canada in the last 5 years has made great advances in the growing, harvesting, and processing of hempseed, and indeed has moved ahead of the EU in the development of raw materials and products for the natural foods, nutraceuticals, and cosmetics industries. In the EU, a yield of 1 t/ha is considered good. In Canada, extraordinary yields of 1.5 t/ha have been realized, at least locally, although in the initial years of hempseed development in Canada yields were often less than 500 kg/ha. In 1999, the year of largest Canadian hemp acreage, yields averaged 900 kg/ha. (Ideally, hemp seed yield should be based on air dry weight—with about 12% moisture. Hemp yields are sometime uncertain, and could be exaggerated by as much as 50% when moist weights are reported.)
The market is rife with misinformation even when CBD is sold as a relatively simple oil or supplement. When it’s squirted into a latte or baked into a cookie, CBD’s uses and effects get even more opaque. The chemical’s loudest advocates make health claims far beyond the current scientific evidence, and its harshest critics often dismiss the compound entirely as just another snake oil in America’s long tradition of health scams. Journalists are starting to get a handle on what CBD actually does and what is actually known about it, but along with researchers and regulators, we’re still playing catch-up when it comes to the people who have pushed the compound into what feels like mainstream overnight success: entrepreneurs.
Executives from Canopy Growth CGC, -1.22% WEED, -1.27% and rival Aurora Cannabis Inc. ACB, -0.88% ACB, -0.83% both discussed their hemp operations on September-quarter earnings calls that included disappointing results related to early recreational pot sales. Aurora declined to comment on the latest developments and Canopy did not make executives available by the time of publication.
A few years ago, the National Academy of Medicine convened a panel of sixteen leading medical experts to analyze the scientific literature on cannabis. The report they prepared, which came out in January of 2017, runs to four hundred and sixty-eight pages. It contains no bombshells or surprises, which perhaps explains why it went largely unnoticed. It simply stated, over and over again, that a drug North Americans have become enthusiastic about remains a mystery.